24 August 2020>: Lab/In Vitro Research
Olmutinib Reverses Doxorubicin Resistance in ETS1-Overexpressing Leukemia Cells
Jiansheng Zhong 1ABE* , Jinli Zhang 2AB , Xiaoyang Yu 3BF , Xing Zhang 1CD , Linping Dian 1CDDOI: 10.12659/MSM.924922
Med Sci Monit 2020; 26:e924922
Figure 4 The effect of olmutinib on protein expression of Bcl-2 and Bax in K562 and K562/ADR cell lines overexpressing ETS1. (A) Representative immunoblot analysis together with relative protein expression of Bcl-2 and Bax in K562 cells (n=3). (B) Representative immunoblot analysis together with relative protein expression of Bcl-2 and Bax in K562/ADR cells (n=3). *** P<0.001 vs. Oe-NC+Dox; # P<0.05, ## P<0.01 and ### P<0.001 vs. Oe-ETS1+Dox. Oe-NC – overexpression-negative control; Oe-ETS1 – overexpression-ETS1; Dox – doxorubicin; Olm – olmutinib.